SCYX

SCYNEXIS, Inc.

SCYX | $1.47 3.52% 3.4% 80K

(0.0% 1d) (0.7% 1m) (-54.8% 1y) (0.0% 2d) (0.0% 3d) (-3.4% 7d) (19.87% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 55,497,617
http://www.scynexis.com
Sec Filling | Patents | 27 employees

(US) SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

fungal infections treatment injection antifungal

add to watch list Paper trade email alert is off

Press-releases

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -12.88% | O: -1.84% H: 1.87% C: -1.25%
scy-247 congress preclinical

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -0.35% | O: -0.35% H: 7.04% C: 3.52%
year update financial results

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
Published: 2024-01-30 (Crawled : 21:00) - globenewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -27.37% | O: -1.79% H: 11.98% C: 7.29%
conference

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
Published: 2024-01-29 (Crawled : 22:00) - globenewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -27.18% | O: 1.54% H: 0.0% C: -1.26%
scy-247 conference preclinical

ASRT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Assertio Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: 2024-01-09 (Crawled : 00:00) - prnewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -29.7% | O: -1.49% H: 1.51% C: -0.5%
ASRT | $0.757 -2.95% -3.04% 710K

Health Technology

| -17.54% | O: 0.41% H: 0.02% C: -5.25%

Final LICY Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that Li-Cycle Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: 2024-01-08 (Crawled : 07:00) - prnewswire.com
LICY | $0.7001 -12.66% 0.23% 3.7M

| 45.51% | O: -0.75% H: 2.62% C: 0.64%
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -24.87% | O: 0.53% H: 6.32% C: 6.32%

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: 2024-01-08 (Crawled : 06:00) - prnewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -24.87% | O: 0.53% H: 6.32% C: 6.32%

SCYX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: 2024-01-07 (Crawled : 12:20) - prnewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| Email alert Add to watchlist
MSS | $1.2 -2.5% 23K

| Email alert Add to watchlist

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
Published: 2024-01-05 (Crawled : 13:30) - globenewswire.com
SCYX | $1.47 3.52% 3.4% 80K

Health Technology

| -26.8% | O: 0.0% H: 0.0% C: -2.58%
scy-247 preclinical

SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
Published: 2024-01-04 (Crawled : 16:00) - prnewswire.com
PAYC 4 | $184.87 -1.07% 0.0% 610K

Technology Services